Patients with gliomas harboring IDH mutations typically present at a younger age compared to IDH wild type gliomas, with a peak incidence between ages of 35 and 44, according to the Central Brain Tumor Registry of the United States (CBTRUS) data base report. Here, IDH2 is linked to brain neoplasm.